Opportunistic Infections Are More Prevalent in Crohn’s Disease and Ulcerative Colitis: A Large Population-Based Study.

Opportunistic Infections Are More Prevalent in Crohn’s Disease and Ulcerative Colitis: A Large Population-Based Study. Inflamm Bowel Dis. 2019 Jul 17;: Authors: Sheriff MZ, Mansoor E, Luther J, Ananthakrishnan AN, Abou Saleh M, Ho E, Briggs FBS, Dave M Abstract BACKGROUND: Opportunistic infections (OIs) are more common in patients with inflammatory bowel disease (IBD); however, there have been limited large-scale studies of OIs in IBD. We investigated the epidemiological characteristics of OI in Crohn’s disease (CD) and ulcerative colitis (UC) using a large population-based database. METHODS: Data were collected from…

Read More

High Immunogenicity of the Pneumococcal Conjugated Vaccine in Immunocompromised Adults With Inflammatory Bowel Disease.

High Immunogenicity of the Pneumococcal Conjugated Vaccine in Immunocompromised Adults With Inflammatory Bowel Disease. Am J Gastroenterol. 2019 Jun 13;: Authors: Pittet LF, Verolet CM, Michetti P, Girardin M, Juillerat P, Mottet C, Maillard MH, Siegrist CA, Posfay-Barbe KM, Swiss Inflammatory Bowel Disease Cohort Study Group Abstract INTRODUCTION: Patients with inflammatory bowel disease (IBD) are predisposed to pneumococcal infections due to their underlying disease and iatrogenic immunosuppression. Vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) is recommended, but with poor take-up and few data available. We performed an open-label, phase…

Read More

Prudence Using Serology to Determine Vaccine-Induced Immunity to Measles and Varicella in Patients With Inflammatory Bowel Disease.

Prudence Using Serology to Determine Vaccine-Induced Immunity to Measles and Varicella in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 Jun 05;: Authors: Caldera F, Farraye FA, Rosh JR, Hayney MS PMID: 31165856 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31165856?dopt=Abstract

Read More

Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease.

Related Articles Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease. World J Gastroenterol. 2019 May 14;25(18):2240-2250 Authors: Gong SS, Fan YH, Han QQ, Lv B, Xu Y Abstract BACKGROUND: When opportunistic infections occur, patients with inflammatory bowel disease (IBD) commonly display a significantly increased rate of morbidity and mortality. With increasing use of immunosuppressive agents and biological agents, opportunistic infections are becoming a hot topic in the perspective of drug safety in IBD patients. Despite the well-established role of opportunistic infections in the…

Read More

Vaccine-Preventable Diseases in Hospitalized Patients With Inflammatory Bowel Disease: A Nationwide Cohort Analysis.

Vaccine-Preventable Diseases in Hospitalized Patients With Inflammatory Bowel Disease: A Nationwide Cohort Analysis. Inflamm Bowel Dis. 2019 May 08;: Authors: Guerrero Vinsard D, Wakefield D, Vaziri H, Karagozian R Abstract BACKGROUND: Inflammatory bowel disease (IBD) entails a higher risk of infections, including those that could be prevented with immunizations. Current Advisory Committee on Immunization Practices and American College of Gastroenterology vaccine recommendations for patients with IBD are based on low levels of evidence. METHODS: We conducted a population-based descriptive cohort study using the US National Inpatient Sample ICD-9 codes from…

Read More

Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children.

Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children. Clin Gastroenterol Hepatol. 2019 Apr 19;: Authors: Nicholson MR, Mitchell PD, Alexander E, Ballal S, Bartlett M, Becker P, Davidovics Z, Docktor M, Dole M, Felix G, Gisser J, Hourigan SK, Jensen MK, Kaplan JL, Kelsen J, Kennedy M, Khanna S, Knackstedt E, Leier M, Lewis J, Lodarek A, Michail S, Oliva-Hemker M, Patton T, Queliza K, Russell GH, Singh N, Solomon A, Suskind DL, Werlin S, Kellermayer R, Kahn SA Abstract BACKGROUND & AIMS: Fecal microbiota transplantation (FMT)…

Read More

Improved Antibody Response to Three Additional Hepatitis B Vaccine Doses Following Primary Vaccination Failure in Patients with Inflammatory Bowel Disease.

Related Articles Improved Antibody Response to Three Additional Hepatitis B Vaccine Doses Following Primary Vaccination Failure in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2019 Apr 03;: Authors: Pratt PK, Nunes D, Long MT, Farraye FA Abstract BACKGROUND: Studies have shown the efficacy of hepatitis B (HBV) vaccination in patients with inflammatory bowel disease (IBD) is impaired, but few data exist regarding the effectiveness of revaccination strategies following primary vaccination failure. Our aim was to analyze the association between administration of additional vaccine doses and hepatitis B surface antibody…

Read More

Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT).

Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT). J Clin Gastroenterol. 2019 Mar 13;: Authors: Allegretti JR, Kassam Z, Fischer M, Kelly C, Chan WW Abstract BACKGROUND: Fecal microbiota transplantation (FMT) is a promising therapy for recurrent Clostridioides difficile infection (CDI). Many patients report altered bowel habits including constipation, bloating, gas and loose stool post-FMT despite resolution of CDI, and the etiology remains unclear. METHODS: This was a prospective cohort study of adult patients with recurrent CDI who underwent FMT (1) via…

Read More

Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis.

Related Articles Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2019 Mar 12;: Authors: Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ Abstract BACKGROUND & AIMS: We performed a systematic review and meta-analysis to evaluate the comparative risk of serious infections with tumor necrosis factor (TNF) antagonists, non-TNF targeted biologics, tofacitinib, and immunosuppressive agents in patients with inflammatory bowel diseases (IBD). METHODS: In a systematic search of publications, through March 18, 2018,…

Read More
<< Go Back